Clinical and radiological features driving patient selection for antiangiogenic therapy in non-small cell lung cancer (NSCLC) by Cesare Gridelli et al.
RESEARCH ARTICLE Open Access
Clinical and radiological features driving
patient selection for antiangiogenic therapy
in non-small cell lung cancer (NSCLC)
Cesare Gridelli1*, Andrea Camerini2, Giovanni Pappagallo3, Angelo Pennella4, Michele Anzidei5, Massimo Bellomi6,7,
Roberta Buosi8 and Rosario Francesco Grasso9
Abstract
Background: The use of antiangiogenic therapy in non-small cell lung cancer (NSCLC) requires thorough evaluation
of patient characteristics in order to avoid potential safety issues, particularly pulmonary haemorrhage (PH). The aim
of this consensus by a panel of experts was to identify important criteria for the selection of patients with NSCLC who
would benefit from antiangiogenic therapy.
Methods: Radiologists and oncologists were selected for the expert panel. The nominal group technique (NGT)
and the Delphi questionnaire were used for consensus generation. The NGT consisted of four steps, the result
of which was used to set the Delphi questionnaire. A final report was generated based on the opinions of the
experts from the panel.
Results: An extremely important prerequisite for the evaluation of an antiangiogenic therapeutic approach in
patients with NSCLC was thorough clinical and radiological analysis of the relationships between tumour and
vascular or anatomical structures (performed in close co-operation by oncologists and radiologists). The panel
identified major parameters to be considered before the use of antiangiogenic treatment, collectively agreeing
on the relevance of tumour cavitation, vascular infiltration, endobronchial growth and thromboembolism for
chest tumour sites, and of the presence of aneurysms, extra-thoracic bleeding, brain metastases or thrombi for
extra-thoracic sites. Moreover, a structured report containing information not only on the tumour but also on the
general vascular status is essential to guide the treatment choice The experts agreed that tumour localization in
the absence of vessel infiltration, cavitation, and the use of antiplatelet therapy are relevant parameters to be
assessed, but their presence should not necessarily exclude a patient from receiving antiangiogenic therapy.
Conclusion: Close co-operation between oncologists and radiologists in the diagnosis, treatment selection, and
assessment of response is essential for ensuring therapeutic appropriateness in the NSCLC setting. It should be
noted that neither the use of antiplatelet therapy nor tumour localisation are to be considered as
contraindications to antiangiogenic treatment.
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Background
Tumour angiogenesis is a hallmark of cancer pathogen-
esis and operates through several mechanisms, typically
mediated by pro-angiogenic factors [1, 2]. Vascular
endothelial growth factor (VEGF) is considered to be the
most important angiogenic mediator of endothelial cell
proliferation and survival [3].
Non-small cell lung cancer (NSCLC) is one of the two
major types of lung cancer, accounting for up to 85% of
lung cancers and is associated with a 5-year survival rate
of 15.9% [4]. Favourable survival outcomes (6-months
progression-free survival [PFS] rate: 74%; 95% CI: 57–
97) in NSCLC patients have been reported using anti-
VEGF antibodies in combination with first-line chemo-
therapy [5]. Phase III studies have demonstrated the
efficacy of the combination treatment with bevacizumab
and carboplatin plus paclitaxel in NSCLC: the survival
of the group assigned to bevacizumab plus chemother-
apy was significantly improved compared with the group
assigned to chemotherapy alone, both in a randomized
trial by the Eastern Cooperative Oncology Group (ECOG)
(median survival: 12.3 months versus 10.3 months, re-
spectively; p = 0.003) [6] and in the BEYOND trial (PFS:
9.2 versus 6.5 months, respectively; p 0.001) [7]. In
addition, the AVAiL (Avastin in Lung) phase III study
showed that cisplatin/gemcitabine plus bevacizumab
(7.5 mg/kg or 15 mg/kg) offers clinical benefit as com-
pared with cisplatin/gemcitabine plus placebo (median
PFS: 6.7 versus 6.1 months, respectively, in the low-dose
group, p = 0.003; 6.5 versus 6.1 months, respectively, in
the high-dose group, p = 0.03) and is well tolerated in pa-
tients with advanced NSCLC [8, 9]. Moreover, in the real
world studies SAiL (Safety of Avastin in Lung) [10] and
ARIES (Avastin Regimens: Investigation of Treatment
Effects and Safety) [11] the safety profile of the combin-
ation treatment of bevacizumab plus standard chemother-
apy was consistent, with a low incidence of grade ≥3
adverse events of special interest, and comparable with
the findings of previous randomized trials. Bevacizumab is
the only antiangiogenic agent currently approved for first-
line NSCLC treatment and its use in combination with
chemotherapy is recommended by international guide-
lines [12–14].
Severe pulmonary haemorrhage (PH) is a relatively un-
common but potentially fatal adverse event that occurs
preferentially in squamous NSCLC; the incidence of
grade ≥3 PH reported during antiangiogenic therapy has
been 0.7–1.9% in the phase III and real-world cohort
studies, where patients with predominantly squamous
cell tumours had been excluded [6, 9–11, 15]. Since a
phase II study on advanced NSCLC [16] reported for the
first time an increased incidence of PH in those with
squamous histology, a consensus report by an interdis-
ciplinary panel has suggested that patients with a history
of PH or showing squamous NSCLC should not be given
antiangiogenic therapy; major blood vessel and bronchial
vessel infiltration may be risk factors for PH and there is
no clear connection between tumour location or cavita-
tion and PH [15]. The report recommended an individual
risk-benefit analysis in NSCLC patients being considered
for therapy.
Imaging is essential for diagnosis and staging of
NSCLC as it helps in determining the size, location and
tumour baseline features [17]. Both Multi-Detector
Computed Tomography (MDCT) [18] and the Crabb
diameter method, which was shown to improve the
determination of the incidence of tumour cavitation
compared with the canonical RECIST criteria [19], have
proved to be useful tools to provide a more accurate
evaluation of tumour characteristics. However, studies
have reported great inter-observer inconsistency during
the selection of antiangiogenic therapy in patients with
NSCLC; a strong collaboration between oncologists and
radiologists, based on international standard guidelines,
should therefore be encouraged to help facilitate the
decision regarding the use antiangiogenic agents in
eligible patients [20].
Most importantly, no imaging criteria that can be used
for predicting antiangiogenic therapy-associated PH
could be clearly identified from the literature. Newer
techniques like computed tomography (CT) perfusion
imaging, magnetic resonance (MR) perfusion/diffusion
imaging or positron emission tomography-computed
tomography (PET-CT) do not provide reproducible re-
sults across different study centres and are not com-
monly used in clinical practice. Determining the relevant
parameters to be assessed, therefore, is an increasingly
important goal for optimal use of antiangiogenic therapy
in patients with NSCLC, particularly in light of the de-
velopment of newer antiangiogenic agents [21]. The aim
of this consensus was to identify the criteria that are
important for the selection of patients with NSCLC who
would benefit from antiangiogenic therapy, by a panel of
oncologists and radiologists, using the Nominal Group
Technique (NGT) and Delphi consensus methods.
Methods
Selection of experts
In order to evaluate potential risk factors of PH and as-
sess the optimal selection criteria for antiangiogenic
therapy in patients with NSCLC, the conflicting scien-
tific and clinical evidence was discussed by a group of
six Italian specialists (three oncologists and three radiol-
ogists). Members of the expert panel were identified
under the following series of criteria [22, 23]: a) interest
in the topic; b) a high level of knowledge and clinical ex-
perience on the topic; and c) motivation to share their
knowledge and experience through the Delphi method.
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Consensus methods
The NGT and the Delphi method were used for this study
[24], under the guidance of expert methodologists for each
technique. The NGT is a method of consensus generation
involving a relatively small panel of experts that express
their opinions, in a non-interactive way, about a “core
question”. After all participants have given their views, a
ranking of the opinions is established by voting. Among its
advantages, this technique can be administered to non-
homogeneous groups (for example, groups composed of
specialists from different areas), and is especially suitable
to cases where achieving a consensus appears particularly
difficult. In the Delphi method, a series of statements to be
evaluated is first defined by the experts. A questionnaire
based on the statements is then administered, in two or
more rounds, to the participants. After each round the
methodologist provides a summary of the answers, in an
anonymous way, and participants are encouraged to revise
their previous answers, reducing differences so that a con-
vergence of opinions eventually develops. These methods
can both effectively be used in medical and health service
research and have been shown to give similar outcomes
[25], but their use in combination has rarely been reported.
Study design
The NGT was conducted following four steps: 1. Gener-
ating ideas: the problem “In your opinion what are the
points worthy of study for the clinical-radiological defin-
ition of NSCLC?” was presented to the expert panel and
the experts responded to it individually and independ-
ently by briefly outlining their ideas on paper; 2. Record-
ing ideas: the ideas from the individual members of the
panel were recorded, and overlapping ideas were deleted
from the list; 3. Discussing ideas: each individual idea
was discussed amongst the panel of experts to determine
clarity and importance of the idea; 4. Voting on ideas:
the discussed ideas were then individually prioritized by
the experts. Each expert came up with five ideas they
considered most important; the highest priority idea was
rated as rank 5, and the least important as rank 1. The
final responses from the experts were tallied to get the
most favoured group outcomes on the problem. Thus,
the NGT was used to gather information about the given
question, and the issues that the expert panel considered
relevant to answer this question were then used to
develop the Delphi questionnaire that was submitted to
the expert panel in a second phase. The overall study de-
sign is summarised in Fig. 1. Results were established
based on the outcomes of the two methods.
Results
Nominal group technique
The NGT helped in identifying a broad area of important
parameters for the evaluation of clinical and radiological
features driving the therapeutic management of patients
with NSCLC. From an original list of 20 parameters or
“ideas”, the NGT led to the identification of six main
areas: status of great vessels, status of lung parenchyma,
non-morphological evaluation parameters of the tumour,
organizational aspects, localisation of the tumour and
tumour morphology. The ideas embodied in these broad
areas were rated, establishing a limit cut-off consensus
percentage of 66%. With these criteria, the expert panel
nominated several points as relevant for the choice of
antiangiogenic treatment in NSCLC. Central versus
peripheral localization of the tumour, ratio of solid to cavi-
tation component of tumours, presence of thrombo-
embolism in great vessels and relationship to non-vascular
adjacent thoracic structures were rated, in this order, as
important by all the participants (100% consensus). Lung-
vessels relationship was rated as important by five out of
six participants, as well as the opportunity of a structured
report, while presence of thromboembolism in peripheral
vessels, use of standardized imaging techniques, general
lung status regardless of the tumour presence and pleural
effusion were rated, in this order, as important by four out
of six participants.
Delphi questionnaire
Based on the results obtained through the NGT, the
Delphi questionnaire was set and answered by the expert
panel to generate a consensus report. The results of the
Delphi questionnaire are summarised in Table 1. The re-
sults of the questionnaire show that in order to prescribe
an antiangiogenic therapy, information on the infiltra-
tion of the tumour into great vessels and mediastinum
was considered most important by all the members of
the expert panel. Complete consensus (100% agreement)
was also reached regarding 5 mm thickness being
Fig. 1 Overview of the study design. NTG, nominal group technique
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inadequate to evaluate infiltration of vessels by com-
puted tomography (CT) scan; the importance of having
an awareness of the potential presence of a thrombus
when considering antiangiogenic therapy; that pleural
effusion is not always a contraindication to antiangio-
genic therapy; that pleural effusion after pleurodesis is not
a contraindication to antiangiogenic therapy; that, for the
chest tumour site, a structured report is a useful tool when
it contains information regarding cavitation, vascular infil-
tration, endobronchial growth and thromboembolism,
and, for an extra-thoracic tumour site, information about
thrombi, extra-thoracic sites of bleeding and the presence
of aneurysms and brain metastases (Table 1).
Broad consensus (>80% agreement) was also reached
on the following: the importance of information on infil-
tration into the bronchi and carina; that 1.5 mm or
3 mm thickness is sufficient for evaluating infiltration of
vessels by CT scan; that compression of a vascular struc-
ture (particularly the aorta) is not a contraindication for
antiangiogenic therapy; that endobronchial tumour
extension may be a bleeding risk factor; that awareness
of the presence of deep vein thrombosis requiring
antiplatelet therapy is fundamental when considering
antiangiogenic therapy; and that it is useful to have a
structured report which contains information on fistulas
and tumour margins (Table 1).
Table 1 Delphi questionnaire consensus report
Statement Respondents
who agreed (%)
1 I feel that to implement an antiangiogenic therapy
is important to know the infiltration of the tumour
into adjacent structures such as:
i. Pleura 0.00







ix. Large vessels 100.00
2 To evaluate vessels infiltration by CT scan in
patients with NSCLC, I think it is sufficient to
have the resolution given by a thickness of:
i. 5 mm 0.00
ii. 3 mm 83.33
iii. 1.5 mm 83.33
3 In the evaluation of treatment with antiangiogenic
therapy I consider essential to know whether or
not a thrombus is present
100
4 In the absence of infiltration of vessels, I think that
tumour site (central or peripheral) is relevant for
treatment
66.67
5 I think that cavitation is a contraindication to
antiangiogenic therapy
66.67
6 I believe that the compression of a major vascular
structure listed below by a secondary
lymphadenopathy is a contraindication for
antiangiogenic therapy
i. Vena cava 33.33
ii. Aorta 16.67
iii. Pulmonary arteries 33.33
iv. Pulmonary veins 33.33
7 I think that proximity of the disease to a large
vessel is not a contraindication to antiangiogenic
therapy
66.67
8 I believe that the alteration of the lung parenchyma




iv. Endobronchial tumour extension 83.33
v. Pleural effusion 0.00
9 In evaluating the feasibility of antiangiogenic
therapy I think it is essential to know the presence
of deep venous thrombosis requiring antiplatelet
therapy
83.33
10 I think that pleural effusion is always a
contraindication to antiangiogenic therapy
0
Table 1 Delphi questionnaire consensus report (Continued)
11 I think that pleural effusion is a contraindication to
antiangiogenic therapy only if it is haemorrhagic
50
12 I think pleural effusion is a contraindication to
antiangiogenic therapy only after pleurodesis.
0
13 For the chest tumour site, I consider that, to be
useful to clinical practice, a structured report should
include at least:
i. Cavitation 100.00
ii. Vascular infiltration 100.00
iii. Fistulas 83.33




14 For the extrathoracic tumour site, I consider that, to
be useful to clinical practice, a structured report




iv. Extra-thoracic bleeding sites 100.00
v. Brain metastases 100.00
vi. Thrombi 100.00
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When considering whether the alteration of the lung
parenchyma may be a risk factor for bleeding, the answers
varied depending on whether the alteration was fibrosis,
bronchiectasis, emphysema, endobronchial tumour exten-
sion, or pleural effusion (Table 1). There was no consensus
regarding whether haemorrhagic pleural effusion is a
contraindication to antiangiogenic therapy. The experts
did agree that tumour localization in the absence of vessel
infiltration, cavitation, and the use of antiplatelet therapy
are relevant parameters to be assessed, but their presence
should not necessarily exclude a patient from receiving
antiangiogenic therapy.
Discussion
Adding an antiangiogenic agent to standard chemotherapy
provides substantial benefit in terms of response rate,
progression-free survival and overall survival in advanced
NSCLC; however, thorough evaluation of the patient as well
as the tumour characteristics is needed to reduce the risk of
serious complications such as PH [16]. The results of the
present consensus addressed several key issues regarding
the selection of patients with NSCLC for antiangiogenic
therapy. Consensus output clearly stated that a detailed
clinical and radiological analysis of the relationships be-
tween a tumour and its surrounding mediastinal structures
is mandatory when considering an antiangiogenic thera-
peutic approach for the treatment of patients with NSCLC.
Tumour infiltration can be a risk factor for PH in patients
with NSCLC undergoing antiangiogenic therapy [20]. The
results of the survey suggested that evaluation of tumour in-
filtration in the mediastinum and major vessels, typically
with a 1.5 mm CT scan resolution, is helpful in assessing
the risk of PH when considering the antiangiogenic therapy.
Tumour site in the absence of vessel infiltration and pres-
ence of a thrombus are important parameters for defining
treatment selection. The contiguity of the tumour to a large
vessel, however, is not a contraindication to antiangiogenic
treatment, nor is the compression of a major vascular struc-
ture by a secondary lymphadenopathy. Moreover, pleural ef-
fusion is not always a contraindication to antiangiogenic
therapy according to the experts involved in the study.
The expert panel also agreed that tumour cavitation is an
important variable that should be examined before antian-
giogenic therapy is used in NSCLC. It is essential to note
that tumour cavitation is not in itself a contraindication to
the use of antiangiogenic therapy, but is an important as-
pect to consider, since it is known to increase the risk of
PH in patients with lung cancer [26]. Appropriate know-
ledge of any pre-existing tumour cavitation can be helpful
in deciding the most appropriate course of treatment. The
expert panel further suggested that it is essential to know of
the presence of any deep vein thrombosis requiring
antiplatelet therapy to prevent any further treatment-
associated complications. In addition, among alterations of
lung parenchyma (fibrosis, bronchiectasis, emphysema,
endobronchial tumour extension, pleural effusion), the
expert panel agreed that only an endobronchial tumour
extension may be considered a risk factor for bleeding.
However, neither the use of antiplatelet therapy nor tumour
localisation should be considered contraindications to an
antiangiogenic treatment approach.
One of the outcomes from the expert panel empha-
sised the importance and the need for a comprehensive
and structured report. In fact, radiological reports lack-
ing key information could lead to the exclusion of pa-
tients from antiangiogenic treatment. The expert panel
agreed that a complete report should include informa-
tion about cavitation, vascular infiltration, endobronchial
growth, thromboembolism, margins, fistulas and lymph-
angitis, and a report for the extrathoracic tumour site
should include at least information regarding aneurysms,
brain metastases, thrombi, extra-thoracic bleeding sites,
fistulas and diverticula. Such a treatment-oriented re-
port, including a description of both tumour and general
vascular status, is essential to guide the choice of treat-
ment by the oncologist. Radiologists play an important
role in diagnosis and assessment of treatment response
in patients with NSCLC. Oncologists should share with
radiologists parameters required for an appropriate risk-
benefit evaluation of available treatments.
The main limitation of the present report is that only
a small number of experts were included in the panel.
Also, the proposed criteria for patient selection have not
been validated in clinical practice. However, the criteria
are based on the clinical knowledge and expertise of
oncologists and radiologists and may be beneficial in re-
ducing the risk of PH with the use of anti angiogenic
therapy in patients with NSCLC.
Conclusions
An expert panel comprising three oncologists and three ra-
diologists examined important criteria/parameters when
selecting patients with NSCLC for antiangiogenic therapy
in order to ensure safety and in particular minimise the
development of PH. Thorough clinical and radiological
analysis of the relationships between tumour and vascular
or anatomical structures (performed in close co-operation
by oncologists and radiologists) was identified as an ex-
tremely important prerequisite. Before antiangiogenic treat-
ment is used it is important to examine tumour cavitation,
vascular infiltration, endobronchial growth and thrombo-
embolism for chest tumour sites, and of the presence of
aneurysms, extra-thoracic bleeding, brain metastases or
thrombi for extra-thoracic sites. Overall, based on complete
knowledge of relevant parameters, the co-operative efforts
of radiologists and oncologists may provide a framework
for the selection of patients and safe use of antiangiogenic
agents for the treatment of NSCLC in a clinical setting.
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